MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The Portuguese Version of Montreal Cognitive Assessment as a screening test comparing Vascular Parkinsonism and Parkinson´s Disease in a hospital cross-section study

A. Velon, M. Mendes, R. Almendra, A. Almeida, M. Correia, C. (Vila Real, Portugal)

Meeting: 2018 International Congress

Abstract Number: 1261

Keywords: Cognitive dysfunction, Dementia, Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Cognition

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: Compare cognitive function between Vascular Parkinsonism (VaP) and Parkinson´s Disease (PD) patients.

Background: Portuguese version of Montreal Cognitive Assessment (MoCA) is a validated screening instrument for cognitive dysfunction and has normative data and cut-off points for mild cognitive impairment and dementia. Most studies consider that early subcortical dementia is more common in VaP patients than in those with PD. Reduced attention span is considered the primarily feature for memory impairment seen in VaP.

Methods: Study conducted in 50 patients (VaP: 16 and PD: 34) with clinically suspected VaP (Zijlmans et al and/or Winikates and Jankovic criteria) and early PD (UK Parkinson´s Disease Society Brain Bank Clinical diagnostic criteria) diagnosed in the last 5 years in a Hospital Movement Disorders Outpatient Clinic. Cognitive assessment included MoCA (version 7.1.). Analyses included normative data of MoCA scores according to age (25-49, 50-64, ≥ 65 and all years) and education level (1-4, 5-9, 10-12, > 12 years and all years) for mild cognitive impairment, MCI (<22) and Vascular Dementia, VaD (<17).

Results: The mean age of the subjects was 72,36 years, 54% were male with no age and sex differences in VaP and PD patients. In both groups, 88% of the patients had ≥ 65 years old and 70% primary education level (1-4 years) with no differences between groups. Mean disease duration (years) was 1,81 (SD: 1,87) in VaP and 3,24 (SD: 1,76) in PD patients. The average MoCA score was 19,62 ± 1.45 (range 16,67 to 22,56) in PD and 19,27 ± 1.64 (range 15,94 to 22,59) in VaP patients. Five patients meet criteria for dementia (VaP: 3, DP: 2) and 38 for mild cognitive impairment (VaP: 12, PD: 26). MoCA cognitive domain scores were analysed according to age and educational level using a multivariate analysis of variance and there were no significant differences between VaP and PD groups.

Conclusions: We don´t find significant differences comparing early diagnosed VaP and PD patients using Portuguese version of MoCA in a hospital cross-section study.

To cite this abstract in AMA style:

A. Velon, M. Mendes, R. Almendra, A. Almeida, M. Correia, C.. The Portuguese Version of Montreal Cognitive Assessment as a screening test comparing Vascular Parkinsonism and Parkinson´s Disease in a hospital cross-section study [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/the-portuguese-version-of-montreal-cognitive-assessment-as-a-screening-test-comparing-vascular-parkinsonism-and-parkinsons-disease-in-a-hospital-cross-section-study/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-portuguese-version-of-montreal-cognitive-assessment-as-a-screening-test-comparing-vascular-parkinsonism-and-parkinsons-disease-in-a-hospital-cross-section-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley